{"id":"NCT01734811","sponsor":"Inmunotek S.L.","briefTitle":"Efficacy and Safety Evaluation in Recurrent Wheezing Attacks","officialTitle":"Randomized Double-blind Placebo-controlled, Parallel, Multi Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm (Wheezing Attacks) for the Evaluation of Efficacy, Security and Clinical Impact.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2016-05","completion":"2017-02","firstPosted":"2012-11-28","resultsPosted":"2020-09-04","lastUpdate":"2021-11-08"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Bronchospasm; Bronchiolitis","Bronchospasm; Bronchitis"],"interventions":[{"type":"BIOLOGICAL","name":"Biological vaccine","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Biological vaccine","type":"EXPERIMENTAL"}],"summary":"The study will be conducted in two hospitals of the same geographic area. It will be included children \\<3-years-old with recurrent wheezing attacks, confirmed by the review of the medical records, in the previous 12 months or a shorter time for those younger than one year.","primaryOutcome":{"measure":"Number of Recurrent Bronchospasm (Wheezing Attacks)","timeFrame":"12 months","effectByArm":[{"arm":"Placebo","deltaMin":299,"sd":null},{"arm":"Biological Vaccine","deltaMin":176,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":2,"countries":["Spain"]},"refs":{"pmids":["21391984","33705665"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":58},"commonTop":[]}}